ANEB Stock Overview
A clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Anebulo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.70 |
| 52 Week High | US$3.30 |
| 52 Week Low | US$0.80 |
| Beta | -1.1 |
| 1 Month Change | 18.88% |
| 3 Month Change | -17.07% |
| 1 Year Change | -29.75% |
| 3 Year Change | -72.36% |
| 5 Year Change | n/a |
| Change since IPO | -76.06% |
Recent News & Updates
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 22
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18Recent updates
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 22Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?
Jul 03Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 07We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth
Nov 19Anebulo Pharmaceuticals to launch private investment in public equity financing
Sep 26Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03
Sep 09Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 28Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 15Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Nov 04Anebulo Pharmaceuticals reports FQ3 results
Jun 21Shareholder Returns
| ANEB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 71.7% | 3.0% | 2.8% |
| 1Y | -29.8% | 8.9% | 24.6% |
Return vs Industry: ANEB underperformed the US Pharmaceuticals industry which returned 8.9% over the past year.
Return vs Market: ANEB underperformed the US Market which returned 24.6% over the past year.
Price Volatility
| ANEB volatility | |
|---|---|
| ANEB Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANEB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ANEB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3 | Richie Cunningham | www.anebulo.com |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Fundamentals Summary
| ANEB fundamental statistics | |
|---|---|
| Market cap | US$42.01m |
| Earnings (TTM) | -US$7.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.6x
P/E RatioIs ANEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANEB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.92m |
| Earnings | -US$7.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANEB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 22:19 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anebulo Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |